Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes

Rapid Communications in Mass Spectrometry

Volumn 27, Issue 1, 2013, Pages 35-50

  Höppner, Sebastian ^a   Schänzer, Wilhelm ^a   Thevis, Mario ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLATION; CONTROLLED DRUG DELIVERY; ELECTROSPRAY IONIZATION; IONS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; SPORTS;

CONTROL PURPOSE; DEACETYLATION; DOPING CONTROL; DRUG CANDIDATES; HUMAN PLASMAS; LOW MOLECULAR MASS; METABOLIC DISORDERS; MODEL SUBSTANCE; PHYSICAL PERFORMANCE; TYPE 2 DIABETES MELLITUS;

RESVERATROL;

EID: 84871339146     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.6421     Document Type: Article

References (45)

1. S. Imai, C. M. Armstrong, M. Kaeberlein, L. Guarente,. Transcriptional silencing and longevity protein Sir2 is an NADdependent histone deacetylase. Nature 2000, 403, 795.
2. M. Kaeberlein, M. McVey, L. Guarente,. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes. Dev. 1999, 13, 2570.
3. S. J. Lin, P. A. Defossez, L. Guarente,. Requirement of NAD and SIR2 for lifespan extension by calorie restriction in Saccharomyces cerevisiae. Science 2000, 289, 2126.
4. L. Bordone, L. Guarente,. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat. Rev. Mol. Cell Biol. 2005, 6, 298.
5. S. Michan, D. Sinclair,. Sirtuins in mammals: insights into their biological function. Biochem. J. 2007, 404, 1.
6. B. C. Smith, W. C. Hallows, J. M. Denu,. Mechanisms and molecular probes of sirtuins. Chem. Biol. 2008, 15, 1002.
7. J. Lin, H. Wu, P. T. Tarr, et al,. Transcriptional coactivator PGC1alpha drives the formation of slowtwitch muscle fibres. Nature 2002, 418, 797.
8. J. T. Rodgers, C. Lerin, W. Haas, S. P. Gygi, B. M. Spiegelman, P. Puigserver,. Nutrient control of glucose homeostasis through a complex of PGC1alpha and SIRT1. Nature 2005, 434, 113.
9. + metabolism and SIRT1 activity. Nature 2009, 458, 1056.
10. K. J. Menzies, D. A. Hood,. The role of SirT1 in muscle mitochondrial turnover. Mitochondrion 2012, 12, 5.
11. A. Brunet, L. B. Sweeney, et al,. Stressdependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303, 2011.
12. D. N. Gross, A. P. van den Heuvel, M. J. Birnbaum,. The role of FoxO in the regulation of metabolism. Oncogene 2008, 27, 2320.
13. F. Picard, M. Kurtev, N. Chung, A. ToparkNgarm, T. Senawong, R. M. De Oliveira, M. Leid, M. W. McBurney, L. Guarente,. Sirt1 promotes fat mobilization in white adipocytes by repressing PPARgamma. Nature 2004, 429, 771.
14. C. Handschin, B. M. Spiegelman,. Peroxisome proliferatoractivated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr. Rev. 2006, 27, 728.
15. F. Yeung, J. E. Hoberg, C. S. Ramsey, M. D. Keller, D. R. Jones, R. A. Frye, M. W. Mayo,. Modulation of NFkappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23, 2369.
16. J. P. Silva, C. Wahlestedt,. Role of Sirtuin 1 in metabolic regulation. Drug. Discov. Today 2010, 15, 781.
17. J. N. Feige, M. Lagouge, C. Canto, A. Strehle, S. M. Houten, J. C. Milne, P. D. Lambert, C. Mataki, P. J. Elliott, J. Auwerx,. Specific SIRT1 activation mimics low energy levels and protects against dietinduced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008, 8, 347.
18. M. Lagouge, C. Argmann, Z. GerhartHines, H. Meziane, C. Lerin, F. Daussin, N. Messadeq, J. Milne, P. Lambert, P. Elliott, B. Geny, M. Laakso, P. Puigserver, J. Auwerx,. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC1alpha. Cell 2006, 127, 1109.
19. J. C. Milne, P. D. Lambert, S. Schenk, et al,. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450, 712.
20. R. K. Minor, J. A. Baur, A. P. Gomes, et al,. SRT1720 improves survival and healthspan of obese mice. Sci. Rep. 2011. DOI: 10.1038/srep00070.
21. N. B. Ruderman, X. J. Xu, L. Nelson, J. M. Cacicedo, A. K. Saha, F. Lan, Y. Ido,. AMPK and SIRT1: a longstanding partnership? Am. J. Physiol. Endocrinol. Metab. 2010, 298, E751.
22. C. A. Blum, J. L. Ellis, C. Loh, P. Y. Ng, R. B. Perni, R. L. Stein,. SIRT1 Modulation as a Novel Approach to the Treatment of Diseases of Aging. J. Med. Chem. 2010, 54, 417.
23. st Scientific Sessions of American Diabetes Association Meeting, San Diego, CA, 2011. Available: http://www.sirtrispharma.com/pdfs/ADA11PosterQi-etal.pdf
24. V. Suri, Y. Qi, M. Davis, A. Cote, E. Lainez, M. Johnson, M. Hirsch, D. Gagne, J. Ellis, G. Vlasuk,. Metabolomic analysis reveals profound impact of SIRT1 activators on carbohydrate and lipid oxidation in multiple tissues. 2011 Cell Symposia: Metabolism and Aging, Cape Cod, MA, 2011. Available: http://www.sirtrispharma.com/pdfs/CellAgingPoster11-Surietal.pdf
25. T. Yoshizaki, S. Schenk, T. Imamura, et al,. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 2010, 298, E419.
26. K. T. Howitz, K. J. Bitterman, et al,. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191.
27. S. Timmers, E. Konings, L. Bilet, et al,. Calorie restrictionlike effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14, 612.
28. N. L. Price, A. P. Gomes, A. J. Ling, et al,. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012, 15, 675.
29. E. Hoffmann, J. Wald, S. Lavu, J. Roberts, C. Beaumont, J. Haddad, P. Elliott, C. Westphal, E. Jacobson,. Pharmacokinetics and tolerability of SRT2104, a firstinclass small molecule activator of SIRT1, after single and repeated oral administration in man. Br. J. Clin. Pharmacol. 2012. DOI: 10.1111/j.13652125.2012.04340.x.
30. C. B. Vu, J. E. Bemis, J. S. Disch, et al,. Discovery of imidazo[1,2b]thiazole derivatives as novel SIRT1 activators. J. Med. Chem. 2009, 52, 1275.
31. V. M. Nayagam, X. Wang, Y. C. Tan, et al,. SIRT1 modulating compounds from highthroughput screening as antiinflammatory and insulinsensitizing agents. J. Biomol. Screen. 2006, 11, 959.
32. International Conference of Harmonisation. 2004. Available: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/ Q2-R1/Step4/Q2-R1-Guideline.pdf
33. S. Kromidas,. Validierung in der Analytik. WileyVCH, Weinheim, 2011.
34. B. K. Matuszewski, M. L. Constanzer, C. M. ChavezEng,. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLCMS/MS. Anal. Chem. 2003, 75, 3019.
35. S. Beuck, T. Schwabe, S. Grimme, N. Schlörer, M. Kamber, W. Schänzer, M. Thevis,. Unusual mass spectrometric dissociation pathway of protonated isoquinoline3carboxamides due to multiple reversible water adduct formation in the gas phase. J. Am. Soc. Mass. Spectrom. 2009, 20, 2034.
36. M. Thevis, M. Kohler, N. Schlörer, W. Schänzer,. Gas phase reaction of substituted isoquinolines to carboxylic acids in ion trap and triple quadrupole mass spectrometers after electrospray ionization and collisioninduced dissociation. J. Am. Soc. Mass Spectrom. 2008, 19, 151.
37. C. P. Chander, G. Raju, G. Mathai, R. Srinivas, K. Gaikwad, R. Bantu, L. Nagarapu,. Electrospray ionization tandem mass spectrometry of 3phenylN(3(4phenylpiperazin1yl)propyl)1Hpyrazole5-carboxamide derivatives: unusual fragmentation involving loss of 11 u. Rapid Commun. Mass Spectrom. 2012, 26, 207.
38. F. Dreiocker, J. Oomens, A. J. Meijer, B. T. Pickup, R. F. Jackson, M. Schäfer,. Structure elucidation of dimethylformamidesolvated alkylzinc cations in the gas phase. J. Org. Chem. 2010, 75, 1203.
39. 2 via rearrangement. J. Mass Spectrom. 2008, 43, 383.
40. T. Walle, F. Hsieh, M. H. DeLegge, J. E. Oatis, Jr., U. K. Walle,. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377.
41. C. Yu, Y. G. Shin, A. Chow, Y. Li, J. W. Kosmeder, Y. S. Lee, W. H. Hirschelman, J. M. Pezzuto, R. G. Mehta, R. B. van Breemen,. Human, rat, and mouse metabolism of resveratrol. Pharm. Res. 2002, 19, 1907.
42. R. H. Wong, P. R. Howe, J. D. Buckley, A. M. Coates, I. Kunz, N. M. Berry,. Acute resveratrol supplementation improves flowmediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis. 2012, 21, 851.
43. L. M. Howells, D. P. Berry, P. J. Elliott, E. W. Jacobson, E. Hoffmann, B. Hegarty, K. Brown, W. P. Steward, A. J. Gescher,. Phase I randomized, doubleblind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 2011, 4, 1419.
44. A. Thomas, S. Guddat, M. Kohler, O. Krug, W. Schänzer, M. Petrou, M. Thevis,. Comprehensive plasmascreening for known and unknown substances in doping controls. Rapid Commun. Mass Spectrom. 2010, 24, 1124.
45. M. Saugy, N. Robinson, C. Saudan,. The fight against doping: back on track with blood. Drug Test. Anal. 2009, 1, 474.